Drug Trial Radar · NCT01482767
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Last checked: Nov 20, 2026Latest source record: Nov 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
262
Actual
Start
Apr 2012
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Sponsor type
- NIH
- First posted
- Dec 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs: pegylated-interferon alfa 2b (PEG-IFN) and ribavirin (RBV). The purpose of this study was to evaluate the effectiveness of giving boceprevir (BOC) together with standard treatment in treating HCV infection in people with HIV-1 and HCV coinfection.
Conditions
- HIV Infections
- Hepatitis C
Interventions
Pegylated-Interferon Alfa 2b (PEG-IFN)Drug
1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
Ribavirin (RBV)Drug
800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
Boceprevir (BOC)Drug
800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24)Time frame: 24 weeks after treatment discontinuation
Locations
43 sites in 2 countries. Site status is shown where the registry gives one.
Alabama CRS
Birmingham, Alabama
University of Southern California CRS
Los Angeles, California
UCLA CARE Center CRS
Los Angeles, California
Stanford AIDS Clinical Trials Unit CRS
Palo Alto, California
UCSD Antiviral Research Center CRS
San Diego, California
Ucsf Hiv/Aids Crs
San Francisco, California
Harbor-UCLA CRS
Torrance, California
University of Colorado Hospital CRS
Aurora, Colorado
Denver Public Health CRS
Denver, Colorado
Georgetown University CRS (GU CRS)
Washington D.C., District of Columbia
The Ponce de Leon Center CRS
Atlanta, Georgia
Northwestern University CRS
Chicago, Illinois
Rush University CRS
Chicago, Illinois
IHV Baltimore Treatment CRS
Baltimore, Maryland
Johns Hopkins University CRS
Baltimore, Maryland
Massachusetts General Hospital CRS (MGH CRS)
Boston, Massachusetts
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS
Boston, Massachusetts
Bmc Actg Crs
Boston, Massachusetts
Wayne State Univ. CRS
Detroit, Michigan
Henry Ford Hosp. CRS
Detroit, Michigan
Washington University Therapeutics (WT) CRS
St Louis, Missouri
Cooper Univ. Hosp. CRS
Camden, New Jersey
New Jersey Medical School Clinical Research Center CRS
Newark, New Jersey
Weill Cornell Chelsea CRS
New York, New York
Columbia P&S CRS
New York, New York
Weill Cornell Uptown CRS
New York, New York
University of Rochester Adult HIV Therapeutic Strategies Network CRS
Rochester, New York
Bronx-Lebanon Hosp. Ctr. CRS
The Bronx, New York
Chapel Hill CRS
Chapel Hill, North Carolina
Duke Univ. Med. Ctr. Adult CRS
Durham, North Carolina
Cincinnati Clinical Research Site
Cincinnati, Ohio
Case Clinical Research Site
Cleveland, Ohio
MetroHealth CRS
Cleveland, Ohio
Ohio State University CRS
Columbus, Ohio
Penn Therapeutics, CRS
Philadelphia, Pennsylvania
University of Pittsburgh CRS
Pittsburgh, Pennsylvania
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
Providence, Rhode Island
Vanderbilt Therapeutics (VT) CRS
Nashville, Tennessee
Trinity Health and Wellness Center CRS
Dallas, Texas
Houston AIDS Research Team CRS
Houston, Texas
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.